Publication
Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review).
Li Yan, Xiaoke Sun, Pengxiao Su
International journal of molecular medicineNov 1, 2026PMID 42788344doi:10.3892/ijmm.2026.5997 PMC13614617Journal ArticleReviewpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Metastatic castration‑resistant prostate cancer (mCRPC) remains an incurable disease characterized by relentless progression and universal resistance to standard therapies. The limited efficacy of immunotherapies in this malignancy reflects an immunosuppressive tumor microenvironment orchestrated…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.